BR0215935A - Combination therapy for treatment of acute leukemia and myelodysplastic syndrome - Google Patents

Combination therapy for treatment of acute leukemia and myelodysplastic syndrome

Info

Publication number
BR0215935A
BR0215935A BR0215935-0A BR0215935A BR0215935A BR 0215935 A BR0215935 A BR 0215935A BR 0215935 A BR0215935 A BR 0215935A BR 0215935 A BR0215935 A BR 0215935A
Authority
BR
Brazil
Prior art keywords
treatment
acute leukemia
myelodysplastic syndrome
combination therapy
pharmaceutical combinations
Prior art date
Application number
BR0215935-0A
Other languages
Portuguese (pt)
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0215935A publication Critical patent/BR0215935A/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TERAPIA COMBINADA PARA TRATAMENTO DE LEUCEMIA AGUDA E SìNDROME MIELODISPLáSICA". A presente invenção refere-se a métodos de tratamento e combinações farmacêuticas para o tratamento de leucemia aguda tal como leucemia mielógena aguda e síndrome mielodisplásica que são fornecidos os métodos de tratamento e combinações farmacêuticas empregam um conjugado citotóxico anti-CD33 em combinação com pelo menos um composto selecionado dentre o grupo consistindo em uma antraciclina e um análogo de nucleosídeo pirimidina ou purina. Métodos preferidos de tratamento e de combinações farmacêuticas empregam gemtuzumab ozogamicina, daunorrubicina e citarrabina."COMBINED THERAPY FOR TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASTIC SYNDROME". The present invention relates to treatment methods and pharmaceutical combinations for the treatment of acute leukemia such as acute myelogenous leukemia and myelodysplastic syndrome which treatment methods and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one. compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamycin, daunorubicin and cytarrabine.

BR0215935-0A 2002-11-06 2002-11-06 Combination therapy for treatment of acute leukemia and myelodysplastic syndrome BR0215935A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
BR0215935A true BR0215935A (en) 2005-08-09

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215935-0A BR0215935A (en) 2002-11-06 2002-11-06 Combination therapy for treatment of acute leukemia and myelodysplastic syndrome

Country Status (10)

Country Link
EP (1) EP1575582A4 (en)
JP (1) JP2006508119A (en)
CN (1) CN1720044A (en)
AU (2) AU2002348178A1 (en)
BR (1) BR0215935A (en)
CA (1) CA2504611A1 (en)
CR (1) CR7804A (en)
MX (1) MXPA05004711A (en)
NO (1) NO20052009L (en)
WO (1) WO2004043461A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
EP1898946A1 (en) * 2005-07-06 2008-03-19 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ATE521366T1 (en) * 2006-05-27 2011-09-15 Faulstich Heinz Dr APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION
CN1994293A (en) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 Application of oridonin in pharmacy
WO2008058021A2 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
PT3300601T (en) * 2007-02-16 2022-04-21 Celator Pharmaceuticals Inc Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
AU2008335772B2 (en) 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
UY37777A (en) * 2017-06-22 2019-01-31 Servier Lab COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD CARE TREATMENT FOR HEMATOLOGICAL CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
BR112020000492A2 (en) * 2017-07-09 2020-07-14 Biosight Ltd. combination cancer therapy
CA3127860A1 (en) * 2019-01-28 2020-08-06 Board Of Regents, The University Of Texas System Metal chelator combination therapy for the treatment of cancer
CN110123825B (en) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 Pharmaceutical composition containing demethoxydaunorubicin
EP4236970A1 (en) * 2020-10-27 2023-09-06 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
EP1309627B1 (en) * 2000-08-08 2009-09-30 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody

Also Published As

Publication number Publication date
AU2002348178A1 (en) 2004-06-03
NO20052009D0 (en) 2005-04-25
WO2004043461A1 (en) 2004-05-27
CA2504611A1 (en) 2004-05-27
EP1575582A4 (en) 2009-03-11
JP2006508119A (en) 2006-03-09
MXPA05004711A (en) 2005-08-03
NO20052009L (en) 2005-06-27
CR7804A (en) 2008-10-29
EP1575582A1 (en) 2005-09-21
AU2010201113A1 (en) 2010-04-15
CN1720044A (en) 2006-01-11

Similar Documents

Publication Publication Date Title
BR0215935A (en) Combination therapy for treatment of acute leukemia and myelodysplastic syndrome
ECSP105178A (en) ARIL UREA COMPOUNDS IN COMBINATION WITH OTHER CITTATIC OR CYTOTOXIC AGENTS FOR CANCER TREATMENT IN HUMANS
MX2022016405A (en) 1'-cyano nucleoside analogs and uses thereof.
BRPI0414062A (en) use of midified cyclosporins for the treatment of hcv disorders
HUP0303271A2 (en) Use of rapamycin for preparation of pharmaceutical composition suitable for cancer treatment
LT2001083A (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
BRPI9809791B8 (en) aminoalkyl glucosamine phosphate immuno-effecting compounds and compositions comprising the same
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
IL152934A (en) Use of a nucleoside in the manufacture of a medicament for treating heapatitis c virus
MXPA05014082A (en) Biaryloxymethylarene-carboxylic acids.
GT200100183A (en) DERIVATIVES OF QUINOLINA AND QUINAZOLINA.
WO2006015357A3 (en) 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
PT1404347E (en) 4'-SUBSTITUTED NUCLEOSID FOR THE TREATMENT OF DISEASES MEDIATED BY HEPATITIS C VIRUS
DE602006014579D1 (en) HETEROALKYL-TIED PYRIMIDINE DERIVATIVES
WO2001016136A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2008057512A3 (en) Imidazopyrazines as protein kinase inhibitors
CL2004000930A1 (en) COMPOUND DERIVED FROM DEFINED FORMULA DIHYDROQUINAZOLINE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF VIRAL INFECTIONS; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND IN THE PREPARATION OF MEDICINES.
AR027355A1 (en) THIAZOLIDINCARBOXILIC ACIDS
EP1749830A4 (en) Curcumol derivatives, the compositions comprising the same and the use of the same in the manufacture of medicament
BRPI0509927A (en) pharmaceutical composition, use of a composition of matter, and use of a therapeutically effective combination of a survivin antisense oligonucleotide and gemcitabine hydrochloride
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
EE200200087A (en) A composition for the treatment of hepatocellular carcinoma
BRPI0415123A (en) use of l-butylphthalide and its pharmaceutical composition
BR0113148A (en) 2-Pyridinamine Compositions and Related Methods
WO2008087558A3 (en) Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements

Free format text: PARA QUE A SOLICITACAO REQUERIDA NA PETICAO NO 020080037113/RJ DE 12/03/2008 SEJA ATENDIDA, APRESENTE DOCUMENTO DE DECLARACAO DE INCLUSAO DE INVENTORES, NO QUAL DEVEM SE MANIFESTAR TODOS OS INVENTORES CONSTITUIDOS NO PEDIDO, UMA VEZ QUE O DOCUMENTO DE CESSAO APRESENTADO NA REFERENTE PETICAO CORRESPONDE A UMA PRIORIDADE QUE NAO FOI REVINDICADA NA FASE NACIONAL, E AINDA A ALTERACAO NAO PODE SER CONFIRMADA PELO DOCUMENTO DE PUBLICACAO INTERNACIONAL.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/44, 31/53, 31/70, 31/445; A61P 35/00

Ipc: A61K 31/44 (2011.01), A61K 31/53 (2011.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law
B08L Application fees: final archiving

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents)

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08I Application fees: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.